Condition: Mitral Valve Regurgitation · Sponsor: Epygon
The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device. The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent. The purpose of this trial is to assess the safety and feasibility of the Epygon™ Transcatheter mitral valve and the transapical delivery system, in adult patients with severe, symptomatic mitral regurgitation.
This description comes directly from the study's public registry record.
Christophe Giot · +33 4 42 95 12 20 · christophe.giot@affluentmedical.com
Always discuss trial participation with your own doctor first.
| Medical University of Innsbruck | Innsbruck, Austria | Recruiting |
| Medical University of Vienna - Department of Surgery, Division of Cardiac Surgery | Vienna, Austria | Recruiting |
| Careggi Hospital Florence Italy Largo Brambilla | Florence, Italy | Recruiting |
| A.O.U. Citta della Salute e della Scienza di Torino | Torino, Italy | Recruiting |
| Dedinje Cardiovascular Institute | Belgrade, Serbia | Not Yet Recruiting |
| Hospital German Trias i Pujol | Badalona, Spain | Recruiting |
| Hospital de la Santa Creu i Sant Pau | Barcelona, Spain | Recruiting |
| Hospital Clinico San Carlos | Madrid, Spain | Recruiting |
| Hospital Virgen de la Arrixaca | Murcia, Spain | Recruiting |
| Hospital Universitario Virgen Del Rocio | Seville, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04775108